Comparison of Curative Effects of HAG and CAG Regimens for Patients with AML and Medium/High-Risk MDS / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 698-701, 2016.
Article
in Zh
| WPRIM
| ID: wpr-360024
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To study the curative effect of HAG and CAG regimens for patients with acute myelocytic leukemia (AML) and high/medium-risk myelodysplastic syndrome (MDS).</p><p><b>METHODS</b>Fifty two patients from January 2010 to January 2014 were enrolled in this study, 32 were diagnosed with AML and 20 with MDS. All the patients were divided into 2 groups: 26 in HAG group (26 cases) and another 26 in CAG group (26 cases). The bone marrow examination, remission rate, PFS, OS and side reaction rates were compared between 2 groups.</p><p><b>RESULTS</b>After treatment, the bone marrow hyperplasia and juvenile cells were decreased significantly. In HAG group, the remission rate was 57.69% and that was 76.92% in CAG group, the difference between these 2 groups was statistically significant (P<0.05), but the survival time was not statistically significant different between 2 groups (P>0.05). The incidence of side reaction in HAG group was 11.54%, that in CAG group was 7.69%, there was no statistically significant difference (P>0.05).</p><p><b>CONCLUSION</b>Both CAG and HAG regimens have shown significant curative effects for acute myelocytic leukemia and high/medium-risk myelodysplastic syndrome.</p>
Full text:
1
Index:
WPRIM
Main subject:
Bone Marrow Examination
/
Myelodysplastic Syndromes
/
Remission Induction
/
Aclarubicin
/
Leukemia, Myeloid, Acute
/
Antineoplastic Combined Chemotherapy Protocols
/
Granulocyte Colony-Stimulating Factor
/
Cytarabine
/
Therapeutic Uses
/
Drug Therapy
Type of study:
Etiology_studies
Limits:
Humans
Language:
Zh
Journal:
Journal of Experimental Hematology
Year:
2016
Type:
Article